Drug Profile
PRX 105
Alternative Names: PRX-105Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Boyce Thompson Institute for Plant Research
- Developer Protalix BioTherapeutics; Yissum Research Development Company
- Class Enzymes
- Mechanism of Action Cholinesterase stimulants; Scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease; Poisoning
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-0 development in Poisoning(In volunteers) in Israel (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-0 development in Poisoning(In volunteers) in USA (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Parkinson's-disease in Israel (IV)